Bellevue Group’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $163M | Buy |
1,169,879
+1,117,127
| +2,118% | +$156M | 3.88% | 5 |
|
|
2025
Q4 | $6.47M | Buy |
52,752
+2,859
| +6% | +$347K | 0.12% | 71 |
|
|
2025
Q3 | $5.54M | Sell |
49,893
-1,523
| -3% | -$173K | 0.12% | 73 |
|
|
2025
Q2 | $5.7M | Sell |
51,416
-3,606
| -7% | -$384K | 0.13% | 80 |
|
|
2025
Q1 | $6.17M | Buy |
55,022
+6,593
| +14% | +$680K | 0.14% | 80 |
|
|
2024
Q4 | $4.47M | Buy |
48,429
+2,402
| +5% | +$216K | 0.09% | 96 |
|
|
2024
Q3 | $3.86M | Buy |
46,027
+7,093
| +18% | +$541K | 0.06% | 101 |
|
|
2024
Q2 | $2.67M | Buy |
38,934
+5,629
| +17% | +$376K | 0.04% | 107 |
|
|
2024
Q1 | $2.44M | Sell |
33,305
-18,000
| -35% | -$1.38M | 0.04% | 105 |
|
|
2023
Q4 | $4.16M | Sell |
51,305
-56,045
| -52% | -$4.36M | 0.06% | 99 |
|
|
2023
Q3 | $8.04M | Sell |
107,350
-5,300
| -5% | -$408K | 0.13% | 95 |
|
|
2023
Q2 | $8.68M | Buy |
112,650
+12,294
| +12% | +$981K | 0.12% | 96 |
|
|
2023
Q1 | $8.33M | Sell |
100,356
-29,987
| -23% | -$2.48M | 0.12% | 96 |
|
|
2022
Q4 | $11.2M | Buy |
130,343
+32,489
| +33% | +$2.57M | 0.15% | 96 |
|
|
2022
Q3 | $6.04M | Buy |
97,854
+22,428
| +30% | +$1.41M | 0.09% | 107 |
|
|
2022
Q2 | $4.66M | Sell |
75,426
-8,024
| -10% | -$497K | 0.07% | 114 |
|
|
2022
Q1 | $4.96M | Sell |
83,450
-73,550
| -47% | -$4.7M | 0.06% | 116 |
|
|
2021
Q4 | $11.4M | Hold |
157,000
| – | – | 0.12% | 111 |
|
|
2021
Q3 | $11M | Buy |
157,000
+46,000
| +41% | +$3.23M | 0.11% | 115 |
|
|
2021
Q2 | $7.64M | Hold |
111,000
| – | – | 0.07% | 127 |
|
|
2021
Q1 | $7.17M | Buy |
111,000
+26,400
| +31% | +$1.7M | 0.08% | 125 |
|
|
2020
Q4 | $4.93M | Sell |
84,600
-39,100
| -32% | -$2.36M | 0.06% | 125 |
|
|
2020
Q3 | $7.82M | Sell |
123,700
-10,800
| -8% | -$749K | 0.11% | 117 |
|
|
2020
Q2 | $10.3M | Sell |
134,500
-10,000
| -7% | -$766K | 0.15% | 105 |
|
|
2020
Q1 | $10.8M | Buy |
144,500
+136,000
| +1,600% | +$9.4M | 0.21% | 83 |
|
|
2019
Q4 | $552K | Sell |
8,500
-543,100
| -98% | -$35.4M | 0.01% | 162 |
|
|
2019
Q3 | $35M | Sell |
551,600
-517,600
| -48% | -$33.8M | 0.65% | 41 |
|
|
2019
Q2 | $72.2M | Buy |
1,069,200
+991,400
| +1,274% | +$65.2M | 1.23% | 26 |
|
|
2019
Q1 | $5.06M | Sell |
77,800
-45,200
| -37% | -$3M | 0.28% | 77 |
|
|
2018
Q4 | $7.69M | Sell |
123,000
-14,500
| -11% | -$1.01M | 0.51% | 51 |
|
|
2018
Q3 | $10.6M | Sell |
137,500
-22,800
| -14% | -$1.72M | 0.67% | 48 |
|
|
2018
Q2 | $11.4M | Sell |
160,300
-6,900
| -4% | -$487K | 0.97% | 39 |
|
|
2018
Q1 | $12.6M | Sell |
167,200
-13,900
| -8% | -$1.1M | 1.25% | 31 |
|
|
2017
Q4 | $13M | Sell |
181,100
-221,441
| -55% | -$16.8M | 1.36% | 26 |
|
|
2017
Q3 | $32.6M | Buy |
402,541
+90,738
| +29% | +$6.94M | 3.41% | 4 |
|
|
2017
Q2 | $22.1M | Buy |
311,803
+21,375
| +7% | +$1.42M | 2.61% | 8 |
|
|
2017
Q1 | $19.7M | Buy |
290,428
+110,928
| +62% | +$7.8M | 2.63% | 6 |
|
|
2016
Q4 | $12.9M | Buy |
179,500
+23,000
| +15% | +$1.71M | 2.63% | 8 |
|
|
2016
Q3 | $12.4M | Hold |
156,500
| – | – | 2.24% | 11 |
|
|
2016
Q2 | $13.1M | Sell |
156,500
-76,800
| -33% | -$6.82M | 2.46% | 8 |
|
|
2016
Q1 | $21.4M | Buy |
+233,300
| New | +$21M | 3.89% | 1 |
|
Other funds holding GILD
VCM
VPM
Bellevue Group's GILD Position: Q1 2026 in Review
Bellevue Group increased its Gilead Sciences (GILD) stake by 2,118% in Q1 2026, buying an estimated $156M and bringing the position to 1,169,879 shares worth $163M. The position accounts for 3.88% of the portfolio, ranked #5.
Bellevue Group first reported a position in GILD in Q1 2016 and has held it in 41 quarters since. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.
- Bellevue Group held 1,169,879 shares of Gilead Sciences worth $163M as of Q1 2026.
- Bellevue Group bought 1,117,127 Gilead Sciences shares in Q1 2026, an estimated $156M.
- Gilead Sciences made up 3.88% of Bellevue Group's portfolio in Q1 2026, its #5 holding.
- Bellevue Group first reported a position in Gilead Sciences in Q1 2016 and has held it in 41 quarters since.
- 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.
Based on Bellevue Group's 13F filing for Q1 2026, filed 15 May 2026.